Opinion|Videos|January 5, 2024
Adverse Events Seen With JAK Inhibitors for Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Clock Touches: An Advanced Balance Exercise for Patients with Cancer
2
Wildfire Smoke and Cancer Risk: What Patients Should Know
3
Family History of Cancer Fuels Oncology Nurse's Passion for Patient Care
4
Balance Exercises for Patients With Cancer: How the Single-Leg Stand Builds Stability
5